Key facts
- Notable investors include General Inception.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Axoiya
- ·The full record, as it builds
Funding rounds
No funding rounds for Axoiya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axoiya
Developer of a phosphotyrosine enrichment technology designed to enhance the detection of protein post-translational modifications for deeper proteomic analysis. The company offers a magnetically-coupled superbinder with high affinity and specificity for rare, low-abundance phosphorylation events, enabling proteomics researchers to achieve comprehensive phosphoproteome coverage.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2023
- Employees
- 4
- Website
- axoiyabio.com/
- Ownership
- Privately Held (backing)
Axoiya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axoiya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axoiya in its N-PORT filings yet. We sweep new filings monthly.